Stock 3759 PHARMARON BEIJING CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Pharmaron Beijing Co., Ltd. Hong Kong S.E.

Equities

3759

CNE100003PG4

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:17 17/05/2024 BST 		5-day change 1st Jan Change
11.28 HKD 0.00% Intraday chart for Pharmaron Beijing Co., Ltd. +5.82% -28.70%
04-30 Pharmaron Beijing's Profit Rises 17% in 2023 MT
04-29 Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pharmaron Beijing's Profit Rises 17% in 2023
MT
Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
MT
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%
MT
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
MT
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%
MT
Pharmaron Beijing Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.
CI
Pharmaron Beijing Co., Ltd. Announces Executive Changes
CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pharmaron Beijing Co., Ltd. authorizes a Buyback Plan.
CI
Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund
MT
Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates
MT
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023, Payable on 26 July 2024
CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Nomura Adjusts Pharmaron Beijing’s Price Target to HK$17.99 From HK$30.92, Keeps at Buy
MT
Pharmaron Beijing Sees Up to 14% Jump in 2023 Profit
MT
Pharmaron Forecasts Up to 19% Rise in 2023 Attributable Profit
MT
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023
CI
Pharmaron Beijing Buys Back Additional Series 2 Bonds
MT
Pharmaron Beijing Buys Back $68 Million of Convertible Bonds Due 2026
MT
Pharmaron Beijing Buys Back 705 Million Yuan of Series 2 Bonds Due 2026
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300759 Stock
  4. 3759 Stock
  5. News Pharmaron Beijing Co., Ltd.